| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23002 |
| Drug | Lutetium (177Lu) vipivotide tetraxetan |
| Brand | Pluvicto® |
| Indication | Lutetium (177Lu) vipivotide tetraxetan in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of adult patients with progressive prostate specific membrane antigen (PSMA) positive metastatic castration resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 09/01/2023 |
| Rapid review completed | 10/02/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/03/2023 |
| Pre-submission consultation with Applicant | 09/05/2023 |
| Full submission received from Applicant | 19/07/2023 |
| Preliminary review sent to Applicant | 06/02/2024 |
| NCPE assessment re-commenced | 05/03/2024 |
| Factual accuracy sent to Applicant | 11/07/2024 |
| NCPE assessment re-commenced | 19/07/2024 |
| NCPE assessment completed | 12/08/2024 |
| NCPE assessment outcome | The NCPE recommends that 177Lu vipivotide tetraxetan (Pluvicto®) not be considered for reimbursement *. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013
